Lesson learned from Eprex-associated pure red cell aplasia

Kidney and Blood Pressure Research

Volumn 30, Issue SUPPL. 1, 2007, Pages 9-12

  Schellekens, Huub ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTISERUM; ASPARAGINASE; BIOLOGICAL PRODUCT; BLOOD CLOTTING FACTOR 8; GROWTH HORMONE; INSULIN; INTERFERON; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT ERYTHROPOIETIN; STREPTOKINASE;

ANAPHYLAXIS; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PURE RED CELL ANEMIA; THROMBOCYTOPENIA;

ANIMALS; AUTOANTIBODIES; CHEMISTRY, PHARMACEUTICAL; EPOETIN ALFA; HUMANS; LEARNING; RED-CELL APLASIA, PURE;

EID: 34548147232     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107095     Document Type: Conference Paper

References (3)

1. Schellekens H: Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002;24:1720-1740.
2. Schellekens H: Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discovery 2002;1:457-462.
3. Schellekens H, Jiskoot W: Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol 2006;24:613-614.